Hyperpolarized 13C MRI for Cancer Immunotherapy

• Status: Not yet recruiting
• Trial end date: 2026-07-31
• Target enrollment: 0
• Participant gender: Female

Summary

The investigators aim to develop an advanced imaging platform, such as dynamic nuclear polarization (DNP) 13C-MRI, MR fingerprinting (MRF) and MR Relaxometry, which combines with traditional anatomical contrast CT, MRI and PET, and integrate blood/urine metabolomics methods. A comprehensive strategy to thoroughly analyze the immune activation of spleen pattern, microstructure, cell density, red blood cell iron content, immune cell glycolysis and metabolic flow rate.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chang Gung Memorial Hospital
• Collaborator: National Science and Technology Council

Criteria

Inclusion Criteria:

1. Newly diagnosed or recurrent gynecological cancer confirmed by histology.

2. Age ≥ 20 years old.

3. Expected to receive immunotherapy.

Exclusion Criteria:

1. Suffering from other malignancies (excluding non-melanoma skin cancer).

2. History of splenic abnormalities (such as splenic damage, cirrhosis-related splenomegaly or primary/metastatic splenic tumors).

3. Insufficient function of bone marrow, liver and kidney.

4. Contraindications to MRI studies (e.g. claustrophobia, cardiac pacemaker, metal implants in the pelvis).

5. Uncontrolled concurrent diseases, including but not limited to kidney stones, persistent or active infection, symptomatic heart failure, unstable angina, cardiac arrhythmias, or mental illness/social situations that limit compliance with research requirements.

6. Pregnant or lactating women.